DFH Pharma, Inc

Funding and NIH signals

• NIH award NIH awarded $965K (SBIR Phase II 5R44AI155312-05, continuation, notice Aug 26, 2026). NIH RePORTER 5R44AI155312-05 (Aug 26, 2026)
  Evidence (1 event)

  • Aug 26, 2026 · NIH RePORTER 5R44AI155312-05
    Organization: DFH PHARMA, INC.; City/State: GAITHERSBURG, MD; Project number: 5R44AI155312-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-08-26; FY total cost (award amount): 965000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: IND-Enabling Development of HIV Maturation Inhibitors Formulated for use as either Oral or Long-Acting Parenterally Administered Agents; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals